Welcome to MS Views and News blog

MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.

Categories

Latest Blog Posts

February 16, 2026

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

  • MS Infusion Treatments
    /
  • MS Drug Therapies
    /
More than 2 years after its original approval, Sandoz’ natalizumab (Tyruko) biosimilar is officially available to patients with multiple sclerosis…
MS Infusion Treatments

February 16, 2026

Do you Know about the 2-TIMES-A-YEAR* OCREVUS and its AVAILABILITY for treating RMS and PPMS TWO different ways?

  • MS Infusion Treatments
    /
  • MS Injectable (Injection) Treatments
    /
  • MS Drug Therapies
    /
As a ~10-minute† subcutaneous injection OR as a 4-hour†/2-hour†‡ intravenous infusion To Learn More, click here: www.ocrevus.com…
MS Infusion Treatments

February 13, 2026

How Does Alcohol Affect MS?

  • MS Research Study and Reports
    /
By Crystal Hoshaw – Published on January 23, 2026Medically Reviewed by Barbara S. Giesser, MD, FAAN, FANA, Dipl. ABLM Note:…
MS Research Study and Reports
Featured image for “Sex, Intimacy, and Multiple Sclerosis”

February 10, 2026

Sex, Intimacy, and Multiple Sclerosis

  • Marketing
    /
  • Multiple Sclerosis
    /
  • Multiple Sclerosis (MS) Symptoms
    /
  • Wellness for MS
    /
February 2026 Sexual relations are a sensitive — and difficult — topic for people with multiple sclerosis (MS), just as…
Marketing

February 9, 2026

ACTRIMS 2026: Blocking C3 protein seen to ease MS severity in older mice

  • MS Research Study and Reports
    /
Complement system own to reduce disease severity in older mice Written by Lila Levinson, PhD | February 9, 2026 The complement system —…
MS Research Study and Reports

February 9, 2026

Mental ill-health in MS: prevalence and causes

  • MS Cognition
    /
  • Memory (Cognition)
    /
  • Mental Health
    /
  • Multiple Sclerosis
    /
  • Multiple Sclerosis (MS) Symptoms
    /
  • Anxiety & Depression
    /
February 2026 – by Prof. Gavin Giovannoni It is now well established that the burden of MS extends far beyond…
MS Cognition

February 7, 2026

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

  • BTK Inhibitors
    /
  • MS Drug Therapies
    /
  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
February 7, 2026 – Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of…
BTK Inhibitors

February 3, 2026

Congress Approves Funding for MS Research Program, PBM Reforms and More

  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
  • National MS Society Related
    /
February 3, 2026 On February 3, 2026, Congress passed a bipartisan FY2026 funding package that included the following: Department of…
MS Research Study and Reports

February 3, 2026

Study Supported by the National Multiple Sclerosis Society Sheds Light on the Brain’s Ongoing Effort to Create Myelin-Making Cells

  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
  • Myelin Repair
    /
January 29, 2026 Researchers from Johns Hopkins Medicine discovered that the brain is continually trying to produce myelin-making cells. Supporting…
MS Research Study and Reports

February 3, 2026

New biomarker may help identify MS patients for BTK inhibitors

  • MS BIOMARKERS
    /
  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
Balance between 2 molecules seen as inflammation marker Written by Marisa Wexler, MS | January 7, 2026 The balance between two immune signaling…
MS BIOMARKERS

Categories

Latest Blog Posts